問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Nephrology

更新時間：2024-06-12

陳呈旭CHEN, CHENG-HSU
  • Principal Investigator
  • Clinical Trial Experience (year)

  • cschen920@yahoo.com

Recruiting Trial

29Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳呈旭

List

49Cases

2022-01-05 - 2029-11-11

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-09-30 - 2029-12-31

Phase II

Not yet recruiting
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
4Sites

Recruiting4Sites

2024-03-15 - 2031-12-31

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)

  • Condition/Disease

    Immunoglobulin A Nephropathy (IgAN)

  • Test Drug

    injection

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2025-08-01 - 2028-12-31

Phase II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
3Sites

Recruiting3Sites

2025-02-15 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-09-21 - 2026-06-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-11-01 - 2030-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2026-02-01 - 2028-05-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2007-10-01 - 2009-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-12-30 - 2031-06-30

Phase II

Active
THE RETIRE TRIAL: A RANDOMIZED PHASE 2 TRIAL OF ADOPTIVE THERAPY WITH TREG ADOPTIVE CELL TRANSFER (TRACT) TO PREVENT REJECTION IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS

  • Condition/Disease

    Kidney Transplantation

  • Test Drug

    TRK-001

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB